RSS
10 May 2022

Zylorion Receives Approval for Phase II Clinical Study for its Proprietary Almond Therapy™

Author: admintech | Filed under: Press Release

First of its kind study to investigate the effects of Almond Therapy in TRD patients receiving intranasal esketamine. CALGARY, AB, May 10, 2022 /PRNewswire/ – PsiloTec Health Solutions Inc., operating as Zylorion Health, (“Zylorion” or the “Company”), a mental health care and psychedelic…

This entry was posted on Tuesday, May 10th, 2022 at 7:13 am and is filed under Press Release. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

«

»